- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing
Experts discuss whether providers should wait for another complete scientific statement from the National Lipid Association (NLA) or new guidelines from organizations like the American Heart Association (AHA) before implementing the 2024 NLA recommendation for universal lipoprotein(a) (Lp[a]) measurement.
EP: 1.Lp(a) in ASCVD and Guideline Recommendations
EP: 2.Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis
EP: 3.The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis
EP: 4.Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease
EP: 5.Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime
EP: 6.How the Genetic Nature of Lp(a) Levels Influences Screening
EP: 7.A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk
EP: 8.The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations
EP: 9.Evidence Supporting 2024 Guidance for Lp(a) Testing
EP: 10.Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing
EP: 11.Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing
EP: 12.FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels
EP: 13.The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies
EP: 14.Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment
EP: 15.Lp(a) Testing: Prevalence and Strategies to Improve Uptake
EP: 16.Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience
EP: 17.Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models
EP: 18.Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management
Video content above is prompted by the following:
The NLA’s 2024 recommendation comes as a “focused update” to its 2019 scientific statement on the use of Lp(a) in clinical practice. Should providers wait for another complete scientific statement from NLA—or for new guidelines from AHA or other organizations—before implementing this recommendation?
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Assessment of Variation in Ambulatory Cardiac Monitoring Among Commercially Insured Patients
August 13th 2025Ambulatory cardiac monitors’ clinical and economic outcomes vary; one long-term continuous monitor brand showed greater arrhythmia diagnosis, fewer retests and cardiovascular events, and lower health care resource use and costs.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
